The Globe and Mail reports in its Saturday, April 29, edition that RBC analyst Maxim Matushansky has reaffirmed his "sector perform" call for Celestica. The Globe's David Leeder writes that Mr. Matushansky's share target fell by a buck to $14 (all figures U.S.). Analysts on average target the shares at $14.33. Mr. Matushansky says in a note: "Celestica reported a solid Q1 above consensus, provided Q2 guidance above consensus, and raised its FY23 outlook. Growth in the ATS (specifically in A&D, healthtech and industrial) and enterprise businesses is offsetting slowdowns in capital equipment and HPS, which we expect to lead to growth slowing in FY23 from the record FY22 levels. We see Celestica's stock as defensive, considering its discounted valuation and positive FCF. Even though Celestica's mix is shifting to higher quality end markets, we believe Celestica's cyclically slower growth in 2023 and macro uncertainty may restrain valuation multiple expansion in the near-term." The Globe reported on July 28 that BMO hiked Celestica to "outperform" from "market perform." It was then worth $10.50. The Globe reported on Oct. 27 and Jan. 25 that RBC rated Celestica "sector perform." It was then worth $11 and $12.85.